An Early View: Stakeholders Respond to FDA's Concept Paper on LLM-SAMD

One brick at a time, FDA has been advancing LLM-based SAMD.  See the approval of draft-report software for ultraound and see the breakthrough status for radiology CXR draft-report software and see FDA's $1.3M contract for accelerating the regulatory science for radiology diagnostic reporting with AI.

There's also the "big story"- in August FDA released a major concept paper for SAMD in an increasingly LLM world.  

By October 19, some 540 comments were submitted.  Up to yesterday, FDA had released 129 of the comments.  I had Chat GPT filter them for "most important ten comments" on which this preliminary article is based.

See e.g. the AMA's press release on its own comment to the FDA - here.

###

AI Corner Chat GPT

###

FDA Generative AI Medical Device Consultation

What the early comments reveal

ChatGPT 6 • October 20, 2026

FDA’s discussion paper on generative AI medical devices asks how to evaluate software that can produce open-ended clinical responses, change over time, and increasingly take actions. The early comments suggest substantial agreement on the need for a flexible framework, but a significant disagreement about what flexibility should mean. The central question is whether stronger supervision and monitoring can justify less evidence before deployment—and what would demonstrate that those safeguards actually protect patients.

What FDA proposed

Released in August, FDA’s paper outlines a possible approach to generative AI-enabled medical devices and poses 26 questions to stakeholders. It is an exploratory discussion paper, not a new rule or guidance. Its scope extends beyond text-based chatbots to multimodal systems, including applications that interpret images and agents that use tools or execute clinical tasks. [1]

The paper begins with two dimensions of risk: what a device does, including how directly it influences or initiates action, and the consequences of an erroneous output. A general explanation of a disease differs from a patient-specific recommendation, which in turn differs from a system that places an order. But the distinctions are not always clean. An apparently informational response can influence treatment, and a conversation can move from education into urgent medical advice.

For evaluation, FDA proposes competency-oriented benchmarking followed by clinical confirmation. Benchmarks would test capabilities such as clinical knowledge, information gathering, communication, recognition of uncertainty, escalation, and staying within scope. Clinical confirmation would then examine whether those capabilities translate into acceptable performance in the intended setting. The paper contemplates evidence proportionate to risk, rather than requiring the same clinical study for every application.

After deployment, monitoring and change control would address evolving models, shifting populations, and failures that initial testing could not fully anticipate. FDA also asks about independent evaluators, synthetic data, foundation-model information sharing, and the additional risks of autonomous agents.

Two of the 26 questions expose the most consequential choices. Question 18 asks whether stronger postmarket monitoring could justify accepting greater premarket uncertainty. Question 15 asks whether performance should sometimes be compared with the care actually available without the device, including delayed care or no intervention. These questions connect regulatory flexibility to patient access, while raising concerns about who bears the risk of getting that balance wrong.

An early but substantial response

This assessment draws on a selection of substantive early letters, largely from September, together with major October responses from the American Medical Association, American Hospital Association, neurosurgical societies, Personalized Medicine Coalition, and U.S. Chamber of Commerce. It also considers University of California Health’s publicly summarized recommendations. The public docket snapshot showed 541 submissions received but only 129 published, with the available docket export extending through September 30. The findings are therefore an interim reading of significant arguments, not a measure of opinion across the completed consultation. [2]

The device and its workflow matter more than the model label

A recurring response is that risk depends on a particular clinical function and its surroundings. How quickly could harm occur? Can an action be reversed? Can a clinician check the original evidence? Does the user have the necessary expertise? FDA already raises many of these considerations; commenters are pressing for clearer ways to translate them into evidence requirements.

The American College of Allergy, Asthma and Immunology offers a concrete example. Advice about anaphylaxis operates under very different time constraints from advice about long-term asthma management. A similar-sounding recommendation can carry a very different risk when there is little time to recognize and correct an error. Newton’s Tree argues that FDA needs an explicit analysis of hazards, controls, and remaining risk more than it needs additional axes on a diagram. [3, 4]

UltraAI contributes a useful distinction between presenting an existing clinical claim and generating a new one. A system that faithfully summarizes a physician’s report is doing something different from one that infers a diagnosis from an image. Even a summary becomes clinically generative when it changes “cannot exclude” into “is present,” or combines findings into a diagnosis that the source never made. Attaching a citation does not establish that the cited material supports the claim. [5]

These arguments favor evaluation at the level of the clinical function. They also challenge the idea that cautious wording or a disclaimer can determine risk. The Chamber adds a separate qualification: a useful risk framework should not silently become a new legal classification system or automatically determine the regulatory pathway. [6]

Supervision is a clinical capability that must be tested

The AMA’s October 16 letter makes one of the strongest arguments in the consultation: meaningful physician supervision requires more than placing a human at the end of an automated process. The reviewer needs relevant information, expertise, time, cognitive capacity, and authority to reject or stop the system. Supervision also consumes resources. A physician working under ordinary clinical pressure cannot be assumed to perform like a specially trained research reviewer with unlimited time. [7]

University of California Health’s summarized recommendations similarly emphasize the deployed combination of model, prompts, information retrieval, safeguards, and workflow. S. Joseph Sirintrapun, writing in a personal capacity from his experience in pathology and informatics, stresses the practical ability to identify consequential errors. The implication is that supervision itself belongs in the validation study. [8, 9]

RADIN and Total Medical Imaging propose a particularly specific radiology application. They ask FDA to exercise narrowly bounded premarket enforcement discretion for AI-generated drafts that remain private to the interpreting radiologist until affirmative specialist sign-off. The radiologist would have the source images, could edit or reject the text, and would control whether anything enters the clinical record. The proposal excludes automatic finalization and independent ordering or triage. This is a requested policy for a defined workflow, not permission already granted by the discussion paper. [10]

The tension with the AMA is productive. RADIN asks how much regulatory credit a tightly controlled specialist workflow should receive; the AMA asks what evidence establishes that the reviewer can provide the assumed protection. A persuasive answer would measure the performance of the human–AI team: errors introduced, errors caught, omissions corrected, review time, and effects on downstream care.

For radiology and pathology, that is a pivotal research question. A draft can improve performance by directing attention to an overlooked finding, or impair it by anchoring the specialist to a plausible error. Interface design and review burden help determine which effect predominates. Measuring the model alone will miss much of the clinical value—and risk.

Industry does not speak with one voice on premarket flexibility

The most important disagreement concerns the trade between evidence before deployment and surveillance afterward. It does not divide neatly into developers seeking flexibility and physicians demanding caution.

Commenter	Position on the trade
AMA	Necessary premarket assurance should not be reduced on the assumption that later monitoring will compensate.
UltraAI	Monitoring generally complements premarket evidence; substitution would require reliable detection and mitigation before harm.
Clearstep	Supports greater premarket uncertainty in exchange for robust, prespecified monitoring and architectural safeguards.
Personalized Medicine Coalition	Supports conditional flexibility when errors are detectable, reversible, and subject to prompt intervention.
American Hospital Association	Supports streamlined pathways and lifecycle monitoring, with developer responsibility and adequate implementation resources.

 

These positions, set out in the respective submissions, identify the real decision facing FDA. [5, 7, 11–13] It is not simply how much monitoring a sponsor promises. It is whether that monitoring can detect the relevant failure early enough for intervention to matter. A readily reversible error differs from a missed diagnosis discovered months later or an autonomous action that cannot be undone.

UltraAI’s caution is especially noteworthy because it comes from a developer. The company argues that reducing premarket evidence can transfer the discovery of uncertainty to patients while giving the sponsor the benefit of earlier entry. Clearstep, by contrast, argues from its experience with hybrid clinical logic and ongoing clinician review that a stronger postmarket program can support greater flexibility. Their differences reflect competing theories of how safety can be demonstrated, not merely different attitudes toward innovation.

The economic question is just as important. The AMA objects to shifting surveillance work and unresolved product risks onto physicians. AHA emphasizes the burden on hospitals, particularly those with limited resources. A framework that depends on continuous clinical review needs a credible answer about who supplies the labor, data access, and funding.

Better benchmarks require better clinical measurement

The comments generally support structured evaluation, but warn against equating examination performance with clinical reliability. Newton’s Tree offers a useful three-part formulation: establish task competency, confirm clinical performance in the intended environment, and maintain assurance during operation. Each answers a different question. [4]

UltraAI proposes scoring the clinical claims within a report against a reference standard. Different wording can express the same correct finding; elegant wording can conceal a false one. For higher-risk uses, the company also urges developers to constrain the range of inputs and outputs where feasible, rather than assume every application needs unrestricted generation. [5]

The ARPA-H ADVOCATE and Johns Hopkins Applied Physics Laboratory team response adds statistical and operational discipline. Repeated answers to the same case are not independent patients. A large synthetic dataset should not overwhelm evidence of weak performance on real cases. And deployment scale matters: a seemingly modest error rate can become a substantial burden when repeated across a large population. [14]

Several submissions also envision shared evaluation infrastructure. UC Health’s summary proposes refreshed, sequestered benchmarks distributed across health systems; AHA favors multiple qualified evaluators rather than a costly bottleneck. Such arrangements could reduce duplication and improve comparability, but would require sustained governance and funding. The consultation is beginning to identify a market for trusted evaluation services as well as a regulatory need for them.

The less obvious failures deserve attention

Some of the most useful comments broaden the discussion beyond hallucination. Nina Vasan’s Stanford Brainstorm letter draws on evaluations of consumer and youth-facing AI to emphasize omissions, harmful affirmation, and risks that build over repeated interactions. An answer can be factually defensible while reinforcing unhealthy behavior or failing to ask the question that would reveal an urgent problem. These examples inform potential medical-device failure modes rather than establish performance rates for regulated devices. [15]

Escalation provides another example. A system can recognize the need for help and still fail if its alert arrives late, reaches nobody, or sends the patient to the wrong service. Newton’s Tree and Stanford therefore emphasize the completed handoff, not merely the generated warning. This turns an apparently linguistic capability into an operational outcome that can be measured. [4, 15]

Luma’s focused response to FDA’s no-device comparator question raises a different concern: in assistive communication, a system may generate apparent patient speech when no meaningful input was supplied. In that situation, silence can be safer than a fluent fabrication. The AMA approaches the comparator issue from an equity perspective, warning against using limited access to care to justify a lower safety standard for underserved populations. Together, these arguments show why access benefits and minimum safety requirements need separate consideration. [7, 16]

Stanford also raises a rarely discussed lifecycle problem: what happens when a patient has come to depend on a service and the product disappears? For longitudinal applications, advance notice, access to records, referral, and transition support can be clinically important. The relationship between patient and product may outlast the business offering it.

Updates and agents make accountability harder

A medical AI application can change without an obvious change to its interface. The underlying model may be replaced, a prompt revised, a retrieval source updated, or a tool given new permissions. Any of these can alter clinical behavior. UC Health’s summarized call for users to know when the AI changes is particularly important: a model that improves on average can still degrade a previously validated use. [8]

This makes upstream information and control essential. Stanford seeks enforceable rights to version information, change notice, incident disclosure, and support for investigations. Newton’s Tree sees voluntary foundation-model master files as potentially useful, but insufficient to demonstrate the safety of a finished device. Accountability is difficult to exercise when a manufacturer cannot identify or control a dependency on which its product relies. [4, 15]

Agents add the ability to act. A system that schedules, orders, or writes to records must be evaluated across the sequence of decisions and tool uses, including its permissions and ability to stop or recover. The ADVOCATE/JHU APL response and Newton’s Tree emphasize these system-level tests. Individual commenters, including C. D. Rowsell Jr. and Tanisha Tejada Thoreau, add proposals for revalidating authority during execution, audit trails, and runtime stopping controls. These are candidates for development and validation, not established FDA requirements. [4, 14, 17]

An AI supervisor introduces a further dependency. A second model may share the first model’s blind spots rather than independently detect them. The monitoring system therefore needs its own evidence of reliability—a point that connects directly with FDA’s radiology research activity.

The overlapping radiology research contract

FDA’s approximately $1.3 million, 18-month research contract with Cognita Imaging illustrates the related evaluation problem. Announced by Cognita Imaging/Radiology Partners in September, the project uses multiple LLM evaluators and radiologist adjudication of important disagreements to study radiology-report assessment across approximately one million examinations. Its aims include scalable evaluation methods, cohort-size requirements, and practical guidance relevant to premarket and postmarket assessment. [18]

The overlap with the consultation is clear: can automated evaluation make clinical assessment more scalable while retaining trustworthy clinical judgment? There is no established formal linkage between the contract and this docket. They nevertheless occupy overlapping parts of FDA’s research agenda—benchmark validity, AI-assisted supervision, and reliable assessment of generated clinical content. The contract is an investment in evaluation methods, not a regulatory authorization or an answer to the broader debate.

What FDA is getting for its effort

The consultation is producing something more useful than a tally of support and opposition. It is identifying the conditions under which a flexible approach might be credible, and the evidence needed to distinguish effective safeguards from reassuring descriptions.

Its most valuable contribution may be to make broad terms testable. “Human oversight” becomes performance under realistic workload. “Escalation” becomes a completed, timely handoff. “Continuous monitoring” becomes a specified ability to detect a failure before harm accumulates. “Change control” becomes the ability to identify, evaluate, and, when necessary, reverse a clinically consequential modification.

FDA is also learning where implementation could fail for reasons beyond model accuracy. Responsibility, information, operational control, and funding may sit with different organizations. A manufacturer may remain accountable while depending on a foundation-model supplier for change information and a hospital for the data needed to detect problems. Resolving those relationships is part of making lifecycle regulation work.

The comments do not yet prove that the proposed methods are sufficiently reliable or affordable. Nor does conditional support establish consensus about how much premarket uncertainty is acceptable. But the submissions are sharpening that disagreement into questions FDA can investigate: which failures are detectable, how quickly, by whom, and with what effective response?

As more October submissions become available, the most valuable additions will be evidence about those questions—comparative workflow studies, measured supervision performance, monitoring costs, and experience from patients and health systems. The initial record has already moved the debate toward the practical terms on which generative AI could earn a place in clinical care. FDA’s next challenge is to turn those terms into proportionate, reproducible evidence requirements.

Selected sources

1. FDA, Considerations for the Regulation of Generative AI-Enabled Medical Devices, August 2026, especially Appendix B’s 26 questions. https://www.fda.gov/media/194242/download

2. Regulations.gov, docket FDA-2026-N-7874, public-comment snapshot reviewed for this assessment. https://www.regulations.gov/docket/FDA-2026-N-7874

3. American College of Allergy, Asthma and Immunology, September 25 comments.

4. Newton’s Tree, response to FDA’s generative AI discussion paper.

5. UltraAI, September 28 comments, especially the summary on pages 3–6.

6. U.S. Chamber of Commerce, October 19 comments.

7. American Medical Association, October 16 comments.

8. Karandeep Singh, public summary of University of California Health’s October 19 response.

9. S. Joseph Sirintrapun, personal-capacity comments, September 8.

10. Total Medical Imaging and RADIN, joint comments on radiologist-supervised report predrafting, September 25.

11. Clearstep, response to FDA’s generative AI discussion paper.

12. Personalized Medicine Coalition, October 19 comments.

13. American Hospital Association, October 19 comments.

14. ARPA-H ADVOCATE and Johns Hopkins Applied Physics Laboratory team response.

15. Nina Vasan, Brainstorm at Stanford, August 19 comments.

16. Christman/Luma, response to Question 15 on counterfactual comparators.

17. C. D. Rowsell Jr. and Tanisha Tejada Thoreau, separate comments on runtime controls and agent governance.

18. Radiology Partners/Cognita Imaging, announcement of FDA report-evaluation research contract, September 16. https://www.radpartners.com/2026/09/cognita-imaging-receives-fda-contract-to-test-new-approach-to-evaluating-generative-ai-in-radiology/

National Kidney Plan, 10/2026: Key Sightlines into CMS Innovation Frames

A new national kidney care plan was a major effort in the Trump-1 administration (2019 here).  One of the leaders, Abe Sutton, now heads CMMI.   

In October 2026, HHS announces an updated Kidney Plan.  Worth tracking. It gives important sightlines into how this CMS views healthcare innovation.

• A Google-AI summary is here.
• The new Kidney Care National Plan, KCNP, home page is here.
• See the 17-page white paper here.
• See the press release here.

###

AI CORNER

###

HHS’s Kidney Care Plan: A Window into How CMS Thinks About Innovation

DaVita’s response exposes a central policy debate: how should government reward innovation while ensuring that established providers face meaningful competition?

HHS’s Kidney Care National Plan offers a revealing look at how federal officials think innovation happens and why it sometimes stalls. For readers following CMS policy, the significance extends beyond dialysis. The plan connects prevention, payment incentives, competition, and regulatory reform. DaVita’s response exposes the central tension: government sees entrenched structures that may impede progress, while a major provider argues that its scale helps deliver it. The next challenge is turning those positions into policy.

A Kidney Strategy with Broader Policy Implications

On October 20, 2026, HHS released its Kidney Care National Plan, outlining an agenda for earlier intervention, better dialysis options, and expanded transplantation. For readers following CMS innovation policy, the document deserves attention well beyond kidney care. It offers an unusually explicit argument about how government payment, regulation, and market concentration can shape—or suppress—innovation.

The HHS announcement describes a department-wide effort spanning payment policy, research, product regulation, and oversight. Its ambitions are broad: prevent kidney failure, expand patient choice, and improve transplantation. The accompanying plan goes considerably further in diagnosing why progress has been inadequate.

Its central contention is that disappointing outcomes reflect the incentives and institutions government helped create. Medicare is consequently both the payer confronting the consequences and a policymaker with considerable responsibility for changing them. The full argument appears in the supplied plan, especially its discussion of competition and prevention on printed pages 4–12.

DaVita’s response supports many of the goals while challenging that diagnosis. The exchange is a useful case study in what “innovation” means to an agency, a payer, and a major provider.

Looking at the Market Government Helped Build

The plan argues that dialysis facility requirements can impose substantial upfront costs on new entrants, including providers pursuing home-based approaches for which conventional facility infrastructure may be less necessary. It also questions whether established payment arrangements offer a durable business case for adopting better technologies.

This is a broader policy inquiry than deciding whether to increase a reimbursement rate. HHS is asking whether the conditions for receiving payment favor particular organizations, facilities, and delivery methods.

For an innovation company, those conditions can matter as much as the quality of its product. A technology may work clinically yet struggle commercially if providers cannot finance its adoption or prospective customers have little incentive to change.

The plan is also unusually confrontational about incumbent behavior. It discusses physician financial relationships, contracting restrictions, bargaining power with insurers, and third-party premium assistance. These are HHS’s concerns and policy arguments; the document should not be read as an adjudication that any particular company has violated the law. Nevertheless, their prominence signals that HHS sees competition policy as part of health innovation policy.

Prevention’s Problem: Who Pays, and Who Benefits?

The most interesting payment problem concerns who benefits from prevention. An insurer or employer may pay today for earlier detection and treatment, while Medicare receives much of the eventual financial benefit if kidney failure is delayed or avoided. Patients can change coverage before those benefits emerge. Providers likewise may have no practical way to capture the value of preventing an expensive event years later.

The plan therefore identifies a mismatch between the party making the investment and the party receiving the return.

That is a consequential diagnosis for CMS. Encouraging prevention through education alone does not solve it. Nor does an additional payment for a screening encounter necessarily create sustained incentives for treatment and follow-up.

The document proposes exploring accountability across the course of disease, earlier intervention, sustainable financing for new technologies, and coordination among payers. Its recommendation to consider a multi-payer summit acknowledges that Medicare cannot fully solve a problem created by patients moving among coverage arrangements simply by changing one Medicare payment.

The difficult implementation questions remain: Who pays upfront? Who receives credit for avoided kidney failure? How long must a model run? How should it distinguish a treatment effect from differences in the patients who enroll?

The plan identifies the economic problem more clearly than it specifies the contractual solution.

CMS Experiments: Better Outcomes Can Still Cost More

DaVita invokes the Kidney Care Choices model as evidence that value-based kidney care can meaningfully improve patients’ lives. CMS’s evaluation supports important parts of that argument—but adds a financial complication.

According to CMS, the model’s second performance year produced improvements in home dialysis, optimal starts to dialysis, and preemptive and living-donor transplantation. Yet it also produced an estimated $304 million net loss to Medicare in performance year 2023. CMS has continued the model through 2027 while changing its financial methodology and participation options.

Those findings deserve to be presented together. Better care is valuable. Better care does not automatically establish that a particular payment model saves money.

The HHS plan also acknowledges the termination of the separate ESRD Treatment Choices model after it failed to achieve its intended results or anticipated savings. The policy lesson is that a plausible incentive mechanism remains an experiment. Participation, enthusiasm, and improved intermediate measures are insufficient substitutes for evaluating the full result.

The proposed direction is to move intervention earlier. The plan points to CMS’s ACCESS model, which tests recurring payments for technology-supported chronic care, with full payment tied to measurable outcomes. Its covered conditions include stage 3a and 3b chronic kidney disease.

The plan indicates that HHS wants CMS to make preserving health a more dependable business proposition. That requires defining an outcome worth purchasing, establishing credible measures, and offering a payment structure under which organizations can deliver it.

DaVita’s Rebuttal: Scale Can Support Innovation

DaVita’s statement contains a particularly direct sentence:

“Where we differ is the suggestion that kidney care has lacked innovation or that scale stands in its way.”

The company describes investments in coordinated care, transplant navigation, proprietary technology, and a clinical innovation being deployed across its centers. It argues that organizational scale supplies the expertise and capital needed to develop improvements and spread them widely.

That is a substantive response. HHS emphasizes the possibility that concentration protects established practices and discourages entry. DaVita emphasizes the possibility that size enables investment and rapid adoption.

Both mechanisms can operate in the same market. A large provider can introduce a meaningful improvement while also benefiting from conditions that make competing delivery models difficult to establish. Evidence of innovation by an incumbent does not, by itself, settle whether the market produces enough innovation or gives patients sufficient choice.

Conversely, identifying concentration does not establish that smaller organizations would necessarily deliver better care. HHS will need evidence that particular changes in entry requirements, contracting, or payment actually improve access, quality, and costs.

DaVita also makes a clinically important distinction: preventing future kidney failure and treating people who already have it are simultaneous obligations. A prevention strategy must preserve effective care for patients whose need for dialysis cannot be eliminated by earlier intervention today.

Transplantation: Innovation Includes Institutional Reform

DaVita emphasizes the shortage of viable organs. HHS also examines the institutions governing organ procurement, allocation, and transplantation: regional monopolies, payment incentives, contractor arrangements, transparency, and accountability.

The difference in emphasis matters. An organ shortage can coexist with avoidable failures to identify donors, support living donation, recover organs, or complete transplantation. The plan treats those organizational processes as legitimate targets for innovation.

The press release connects this agenda to living-donor assistance, transplant system oversight, and a proposed national expansion strategy.

This also reveals a tension within the administration’s approach. The plan favors reducing barriers and limiting unnecessary regulation, while calling for stronger accountability and enforcement in selected areas. In practice, its proposed federal role is highly active: redesign payment, reconsider entry requirements, scrutinize market behavior, modernize procurement, and enforce performance expectations.

What Happens Next Matters More Than the Announcement

Many recommendations say HHS “should consider” an action or “could” explore a model. The plan itself does not establish a new nationwide prevention benefit, finalize a payment methodology, or complete the proposed regulatory reforms.

For CMS observers, the useful next questions are concrete:

• Does a new model reach patients early enough to change disease progression?

• Can new providers participate without reproducing the infrastructure of incumbent organizations?

• Are outcomes measured over a credible period?

• Do payments reward improvements that would otherwise not occur?

• Are patients already dependent on dialysis protected as incentives change?

The document’s larger significance is its willingness to examine the relationship between public policy and private business models. HHS is arguing that innovation depends on what the healthcare system makes financially possible, attractive, and scalable. DaVita is arguing that established organizations already possess important capabilities for delivering that progress.

Effective policy will require CMS to preserve those capabilities while making room for approaches that the existing system has little reason to adopt.

Key Takeaways and Surprises

1. HHS is questioning the market structure its own rules helped create. Facility requirements and payment arrangements are being examined as possible barriers to innovation and entry.

2. Prevention faces a financial coordination problem. The organization paying for early intervention may never receive the savings. The proposed multi-payer discussion acknowledges that changing Medicare alone may be insufficient.

3. A model can improve care while increasing Medicare spending. Kidney Care Choices illustrates why clinical gains and financial performance must be evaluated separately.

4. DaVita and HHS disagree about the role of scale. HHS emphasizes protection from competition; DaVita emphasizes investment capacity and the ability to spread improvements. Both claims require evidence.

5. “Less regulation” comes with an active federal agenda. The plan combines easier market entry with stronger oversight, scrutiny of business practices, and accountability for transplant organizations.

6. Innovation includes changing institutions. Procurement arrangements, donor support, referral processes, and payment incentives can influence outcomes alongside new drugs and devices.

7. The plan’s diagnosis is more definite than its implementation. Its criticism of existing structures is forceful, but many remedies remain proposals to consider. The decisive developments will be specific model designs, payment terms, and regulatory actions

8. 
   

##

What's the logic of Da vita's rapid disagreement ???

##

Yes—DaVita is explicitly putting its disagreement on the record. But it has chosen a fairly careful form of disagreement: support the administration’s goals, challenge its characterization of the industry, and offer continued cooperation. Whether responding within roughly four hours was smart depends partly on what HHS said publicly beyond the written plan; the exact interval hasn’t been verified here.

Your concern is reasonable. The sentence “Where we differ…” is conspicuous. It ensures that the response cannot be mistaken for an uncomplicated endorsement.

There are several reasons that might nevertheless be a calculated choice:

• The criticism threatens DaVita’s legitimacy, not just a payment rate. HHS is suggesting that established market structures impede progress. Silence could allow the narrative to harden that large dialysis companies are obstacles to better care.
• The audience includes investors, employees, physicians, and patients. A plausible purpose of the rapid response is to reassure those groups that the company has an answer and intends to defend its role.
• DaVita needs to remain a potential implementation partner. Its emphasis on existing capabilities makes the argument that HHS can achieve some of its goals by working with the company.

The statement is diplomatically constructed. It begins with shared urgency, credits the plan with reflecting DaVita’s priorities, identifies a narrow disagreement, and closes with cooperation. It avoids naming or criticizing individual officials. That is controlled pushback, rather than a declaration of war.

But there is a strategic weakness: DaVita partly answers a broader structural criticism with examples of its own innovation. HHS could readily respond: “We did not say you have never introduced anything useful. We said the market could deliver more innovation with stronger competition.” Similarly, saying that scale finances innovation does not resolve whether particular contracting arrangements inhibit competitors.

The paragraph insisting that prevention must not be conflated with lifesaving dialysis is also pointed. It could be read as a necessary defense of current patients—or as suggesting that HHS does not understand an elementary clinical distinction. That is where the tone risks becoming irritating to officials.

On balance, a public response was defensible; the speed and explicit disagreement were optional. A softer formulation could have preserved the substance: “Achieving these goals will require both new entrants and the investment and clinical capabilities of established providers.”

The more revealing question is whether DaVita privately briefed HHS before issuing the statement. Advance notice could make this routine stakeholder positioning. A surprise rebuttal, hours after a flagship announcement, carries more relationship risk. The public statement alone does not tell us which occurred.

##

One more time...why Da Vita says "something" today instead of "nothing" ???

##

Silence was a perfectly reasonable option. The earlier answer overstated the risk that silence would be interpreted as agreement.

The argument against silence is that HHS had publicly challenged the industry’s structure and incentives. DaVita might want investors, employees, and physician partners to hear promptly that it disputes the implication that its size obstructs innovation. That is a reason to respond—but it does not require an immediate public rebuttal.

Silence would have offered several advantages:

• Let HHS have its announcement without creating a second story about industry disagreement.
• Allow private conversations to clarify which criticisms might become actual policy.
• Preserve the opportunity to respond later with evidence and specific proposals.
• Avoid defending the existing system before knowing precisely what changes HHS intends.

A company does not concede a policy argument by declining to contest it on announcement day. It could also issue a short statement welcoming prevention and patient choice, leaving its objections for private meetings or subsequent comments.

The strongest reason for an immediate rebuttal would be a concrete need to reassure stakeholders—for example, substantial investor concern or damaging public allegations. We have not established that such a need required this particular response.

So your instinct is sound: given a potentially sensitive agency and an exploratory plan, public restraint combined with vigorous private engagement could have been the smarter opening. DaVita’s statement was measured, but measured disagreement can still be unnecessary disagreement at that moment.

Four Transcripts and a Sale: LabCorp Adopts Myriad "Prenatal Health" Assets

Just days after LabCorp agrees to acquire BioReference from OPKO, LabCorp agrees to buy Myriad Prenatal Health assets for $210M.

Here, we let Chat GPT write the full case, including the assets, their origins, and how Myriad's public discussion of the business evolved over four quarters.

As always with these reports, they are AI generated reported and not ground truth.  However they service as examples of current AI capabilities to understand requests, research, organize, and write.

Find the 11-page PDF report   HERE.

#

#

Summary.  Myriad’s $210 million prenatal divestiture marks a strategic retreat from a business assembled through acquisitions and expanded through internal innovation. Labcorp gains four products, an established customer base, and FirstGene, launched only three months earlier. Across four earnings calls, management’s narrative shifted from recovery after ordering disruptions to persistent commercial weakness and portfolio review. The evidence does not establish that software problems caused the sale. A stronger interpretation combines disappointing recovery, competitive pressure, reimbursement friction, and oncology investment priorities. For Labcorp, the transaction offers consolidation and integration opportunities; for Myriad, it exchanges uncertain future growth for cash and strategic focus.

Myriad’s Prenatal Exit:

What Four Earnings Calls Reveal
 About the Labcorp Transaction

Analysis as of October 20, 2026

The transaction. Myriad has agreed to sell its Prenatal Health testing business to Labcorp for $210 million in cash, plus inventory at closing. Labcorp projects approximately $160 million of first-year revenue, slight first-year adjusted earnings accretion, and profitability reaching its average Diagnostics segment margins by the end of year two. Closing is expected by early 2027, subject to regulatory clearance and other conditions. These are announced expectations, not completed results. The joint announcement is available here. Labcorp

The SEC filing adds useful substance. This is an asset transaction involving specified assets and liabilities, employee offers, a patent license agreement, and transition services. It is therefore more than a transfer of four trademarks, but it is not an acquisition of Myriad itself. The contractual initial outside date is February 19, 2027, with a potential regulatory extension to October 19, 2027. Certain regulatory termination circumstances could require Labcorp to pay a $10.5 million fee. sec.gov

What “Prenatal Health” means at Myriad. The company’s dedicated prenatal screening webpage describes a portfolio spanning reproductive carrier assessment, fetal chromosome screening, fetal single-gene risk assessment, and early fetal-sex prediction. The four products have distinct purposes:

Product	Principal purpose	Place in the portfolio
Foresight	Identifies carriers of inherited conditions that could be transmitted to offspring	Relevant before pregnancy as well as during pregnancy
Prequel	Uses maternal blood to screen for fetal chromosomal conditions	Myriad’s established noninvasive prenatal screening product
SneakPeek	Predicts fetal sex from early pregnancy	A consumer-facing offering, including at-home access
FirstGene	Combines patient carrier status, fetal single-gene risk, fetal chromosome screening, and fetal RhD assessment	An integrated prenatal assay with one maternal blood draw

Myriad markets FirstGene for use beginning at eight weeks, without requiring a reproductive-partner sample. Its four components should not be confused with four separate acquisitions. Nor should its carrier component be assumed to reproduce the full breadth of every Foresight panel. Myriad Genetics

An important boundary: Myriad is selling prenatal testing, not all testing sold through women’s-health practices. Historically, its Women’s Health business included both prenatal products and hereditary cancer testing for unaffected patients. MyRisk remains in the Cancer Care Continuum category. Thus, the transaction does not imply abandoning OB/GYN relationships or hereditary breast and ovarian cancer assessment. investor.myriad.com

Where the assets came from—and what Myriad paid. The portfolio combines two acquisitions with subsequent development.

Origin	Date	Financial terms	Principal contribution
Counsyl acquisition	Announced May 28, 2018; completed July 31, 2018	$375 million announced; subsequent SEC reporting recorded $405.9 million of total consideration	Foresight and the prenatal screening business then branded Prelude, subsequently Prequel
Gateway Genomics acquisition	November 1, 2022	$67.5 million upfront, with up to $32.5 million contingent consideration	SneakPeek and its consumer distribution capabilities
Myriad product development	Subsequent years; FirstGene commercially launched July 21, 2026	No separate FirstGene acquisition price identified	Integration and extension of prenatal technologies into FirstGene

The Counsyl announcement and closing release establish the 2018 chronology. The Prelude-to-Prequel lineage is also documented in the scientific literature. investor.myriad.com

The $375 million versus $405.9 million distinction deserves attention. The SEC acquisition note reports $278.5 million in cash and approximately three million Myriad shares valued at $127.4 million. Those shares were valued at the closing-date market price. The widely cited announcement price therefore differs from the subsequently recorded consideration. sec.gov

Gateway should not casually be described as a $100 million acquisition: that was the maximum upfront-plus-contingent opportunity. Myriad’s 2024 annual report valued the remaining Gateway contingent consideration at zero because achievement of the targets was not considered probable. myriad.gcs-web.com

Using Counsyl’s announced price plus Gateway’s upfront payment produces $442.5 million. Substituting Counsyl’s subsequently reported consideration produces $473.4 million. Both substantially exceed today’s $210 million headline sale price.

That comparison is striking, but it is not an investment-return calculation or an accounting loss estimate. The purchases and sale have different asset and liability boundaries; Myriad operated the businesses for years; cash flows occurred in the meantime; and additional development spending created products that did not exist at acquisition.

The original strategy was broader than prenatal testing. In 2018, Myriad envisioned combining Counsyl’s reproductive products with hereditary cancer testing to increase physician reach and provide a comprehensive women’s-health offering. In 2022, Gateway added an earlier consumer entry point: families buying SneakPeek could become aware of Myriad’s other genetic tests. investor.myriad.com

One interpretation is that the 2026 sale reverses that organizing principle. The earlier strategy emphasized a shared customer and life-stage relationship. The emerging strategy emphasizes disease-specific investment, particularly cancer. A common ordering physician does not necessarily make two businesses equally attractive destinations for capital.

The Four Call Record

The four-call record. The relevant window is Q3 2025, Q4 2025, Q1 2026, and Q2 2026. Myriad’s next quarterly call is November 4, after this announcement.

The reported prenatal figures provide an anchor for interpreting management’s language:

Reported quarter	Prenatal revenue	Revenue change, year over year	Volume change, year over year
Q3 2025	$44.5 million	+2%	−3%
Q4 2025	$44.9 million	Flat	−6%
Q1 2026	$41.9 million	−15%	−12%
Q2 2026	$39.8 million	−16%	−9%

These are the prenatal product-category figures, not total Women’s Health revenue. The Q2 call rounded revenue to $40 million; the financial table reports $39.8 million. investor.myriad.com

November 3, 2025: recovery remained the working assumption. On the Q3 call, management described improvement after the second-quarter ordering disruption. Legacy Prequel and Foresight volumes were approximately flat year over year. The broader category’s 3% volume decline reflected lower SneakPeek demand, an important distinction between the clinical-testing narrative and the aggregate figures. Roic AI

Analysts Puneet Souda and David Westenberg pressed on competitive share shifts and why the ordering-system effects persisted. Management’s explanation was that large customers already used multiple laboratories and had shifted volume away during the disruption. Fixing the operational problem did not automatically restore their orders.

FirstGene remained a prospective growth catalyst. Nevertheless, oncology was already the first strategic priority, while prenatal and mental health were expected to grow within disciplined resource allocations. The emerging hierarchy preceded the sale: prenatal remained strategically useful, but oncology had first claim on incremental investment. Roic AI

February 23, 2026: the recovery timetable became more qualified. On the Q4 call, management described renewed prenatal volume softness and warned of a difficult first-quarter comparison. It still anticipated recovery from Q2 onward, supported by a more focused sales effort and FirstGene.

Analysts asked whether competition was contributing and how widespread the remaining customer problem was. Brian Donnelly said accounts unaffected by the ordering issue were growing at or above market. Sam Raha described the original implementation as a “self-induced error” and said the company had reviewed its other ordering systems.

FirstGene remained scientifically encouraging, but the CFO said guidance did not assume a sizable direct contribution from it. The product could also reopen conversations about the existing portfolio.

The important change was a more conditional recovery thesis: customer reactivation, commercial execution, and a new-product conversation all needed to work. The Motley Fool

May 5, 2026: analysts challenged the recovery premise directly. On the Q1 call, Brandon Couillard questioned whether annual prenatal volume growth remained realistic, given weak year-over-year results and only modest sequential improvement.

Management pointed to a dedicated prenatal sales team and FirstGene. Crucially, Raha said the order-to-report operational problems had been absent for several quarters. The remaining challenge was commercial execution.

The call also clarified FirstGene’s economic thesis: Myriad intended to launch using existing billing codes, expected higher average revenue per test, and believed that would more than offset somewhat higher processing costs. A dedicated code was a possible later development.

This was still an investment-and-recovery story. But it was explicitly no longer a story about waiting for broken software to be repaired. The unresolved question was whether restored operations and differentiated science would translate into renewed ordering and attractive economics. investing.com

July 30, 2026: disappointing execution became a portfolio question. On the Q2 call, management acknowledged less progress than expected in prenatal, citing sales-force expansion timing and competitive dynamics. It reported declines in both volume and average revenue per test. FirstGene had launched the previous week, and some customers were returning to trial it.

At the corporate level, management described a rigorous portfolio evaluation. The accompanying release connected the strategic review to growth, profitability, and liquidity. Myriad reduced its annual revenue outlook and suspended adjusted EBITDA guidance while assessing its operational initiative, Ascend.

The question had changed from how quickly prenatal would recover to where Myriad should allocate capital. That is the clearest public bridge to the October transaction. It does not establish when negotiations began or that management had already decided to sell during the July call. investing.com

Could a software problem really explain the divestiture? Your skepticism is warranted. The evidence supports a narrower causal chain:

• Management attributed an initial loss of customer volume to the ordering rollout.
• Management repeatedly distinguished fixing operations from recovering customer orders.
• Subsequent disclosures broadened the problem to commercial execution, competition, and reimbursement.
• The eventual sale was presented as the outcome of a strategic review.

The plausible mechanism is persistent customer displacement after a temporary disruption. A practice that already sends specimens to several laboratories can redirect orders quickly. Once another laboratory becomes the established workflow, the original provider must win those orders back.

But plausibility is not proof of magnitude. Public disclosures do not quantify how much lost revenue was attributable to the implementation, identify the affected accounts, or isolate the effects of competitor offerings and payer behavior. They certainly do not demonstrate that the software episode was the decisive reason for selling.

The stronger interpretation is that prenatal’s recovery disappointed while other businesses competed for management attention and investment. The incident may have contributed to that situation; the transaction reflects a broader judgment about ownership and capital allocation.

What the price and revenue tell us. The $210 million headline price represents approximately 1.31 times Labcorp’s projected first-year revenue. Myriad’s latest four reported prenatal quarters total approximately $171.1 million; annualizing Q2’s $39.8 million produces $159.2 million. Labcorp’s $160 million forecast is therefore close to the latest quarterly revenue pace. These are calculations from the disclosed figures, not company-provided valuation multiples. Labcorp

That alignment suggests a transaction underwritten around the current business, with potential improvement to follow. It does not demonstrate that Labcorp assigned FirstGene little value: the companies have not disclosed a product-level valuation or revenue bridge.

Nor does Myriad’s claim of growth accretion mean selling the business increases total revenue dollars. Removing a slower-growing or declining business can improve the remaining company’s percentage growth rate while reducing its size. Profitability improvement depends on the earnings contribution sold, expenses eliminated, and overhead left behind.

Myriad ended Q2 with $115.2 million in cash and reported $30.8 million of first-half adjusted free-cash outflow. Against that background, $210 million of gross proceeds is financially consequential, although it cannot simply be added to June cash to forecast the closing balance. sec.gov

Why Labcorp can see opportunity in a business Myriad is exiting. Labcorp already offers MaterniT prenatal screening and Inheritest carrier screening. Its MaterniT lineage includes the 2016 Sequenom acquisition. It also markets a combined prenatal collection kit designed to simplify ordering and specimen handling. This acquisition expands an established reproductive genetics business. International Distributors

The potential benefits are therefore partly operational: serving additional accounts through existing infrastructure, spreading costs across greater volume, coordinating collection and ordering, and choosing how to position overlapping and differentiated assays.

Those are analytical possibilities, not disclosed integration commitments. The announcement does not specify which brands, laboratories, platforms, or commercial arrangements Labcorp will ultimately retain. Its two-year margin target indicates that integration matters; the buyer is not promising immediate achievement of mature segment profitability.

For Myriad, selling can be rational even if FirstGene is promising. The relevant comparison is between the risk-adjusted value of continuing to fund prenatal and the value of cash, reduced complexity, and investment capacity elsewhere. For Labcorp, an existing operating platform may change that calculation.

The BioReference connection. The two announcements occurred five days apart. On October 15, Labcorp agreed to acquire selected BioReference assets for $722 million upfront, subject to adjustment, plus a possible $150 million 4Kscore earnout. Labcorp projected approximately $250 million in first-year revenue from that transaction. Both transactions remain subject to closing conditions. Labcorp

Announced acquisition	Headline upfront price	Projected first-year revenue	Simple price/revenue ratio
Selected BioReference assets	$722 million	Approximately $250 million	2.89×
Myriad Prenatal Health	$210 million, plus inventory	Approximately $160 million	1.31×

These ratios are descriptive, not directly comparable valuation judgments. They omit differences in margins, growth, liabilities, intellectual property, earnouts, and integration requirements.

The shared strategic pattern is more instructive: sellers are narrowing their focus while Labcorp is expanding the range and scale of diagnostic services it can operate. The same laboratory business can represent organizational complexity to one owner and an attractive addition to another.

Details to watch in the November discussion. The purchase agreement specifies that Myriad retains pre-closing accounts receivable. Selling the operating business therefore does not transfer every legacy collection issue to Labcorp. It also distinguishes purchased assets from shared systems and other retained assets, reinforcing that separation itself requires work. sec.gov

The most useful additional disclosures would be the business’s earnings contribution, stranded overhead, expected separation costs, net proceeds, and commitments to FirstGene development. Without those, it is premature to describe either an obvious bargain for Labcorp or a fully quantified financial improvement for Myriad.

The five most surprising features

1. Counsyl’s familiar $375 million price understates the subsequently reported consideration. The SEC recorded $405.9 million. Adding Gateway’s $67.5 million upfront payment makes the historical acquisition spending substantially larger than the current sale price—even before subsequent development investment. That is a revealing capital-allocation comparison, although not a measure of realized loss. sec.gov

2. FirstGene was commercially launched only 91 days before the sale announcement. Labcorp is acquiring a newly introduced platform alongside established products. The public record offers too little commercial history to treat the sale as a verdict on FirstGene’s market success or failure. globenewswire.com

3. The old women’s-health bundling strategy is being unwound selectively. Myriad retains hereditary cancer testing, including testing delivered through women’s-health practices. What is being separated is the reproductive portfolio that earlier acquisitions were intended to combine with it. investor.myriad.com

4. Labcorp’s first-year forecast almost exactly matches the latest quarterly revenue pace. Annualized Q2 prenatal revenue is $159.2 million versus Labcorp’s approximately $160 million forecast. The announced economics appear grounded in the existing business rather than requiring an immediate dramatic rebound. sec.gov

5. Labcorp is buying into a field where it is already a substantial participant. Existing MaterniT and Inheritest capabilities make this a consolidation and integration opportunity, with FirstGene adding a distinct product proposition. The central strategic wager is that the portfolio will be worth more within Labcorp’s operating system than as an investment priority within Myriad. That final proposition is the deal’s economic hypothesis—not yet its demonstrated outcome. International Distributors

##

Time for Pathology to Follow Radiology's Lead at FDA; Deep Dive on the FDA Radiology AI Contract

Over the last several months, this blog has covered rapidly advances in AI software that will prepare radiology and pathology reports ready for human review, validation, and sign-out.  

Radiology at Lightning Speed

The scale tends to be bigger in radiology, and the benchmarks further.  For example, AIDOC gets Breakthrough Status for FIRST READ, meaning it's well along in the FDA review pathway for software that drafts a full reading (ready-to-review) of chest x-rays.  And raises $150M (here, here).  See also breast ultrasound approval here.  See survey here.

Pathology Putters

I'm just back from PathVisions, the digital pathology conference.  Here on the pathology side, we see some demo's of "RUO" software that gets close to generating prostate pathology reports.  

• But here in Path World, you'd fall out of your chair if a speaker at Path Visions calmly addded that his company was WELLunder FDA review, had WON its FDA breakthrough status, or had raised $150M.   

FDA Invests in Exciting Radiology Diagnostic Science

Another way radiology is ahead - FDA gave a $1.3M contract not to develop a particular software, but to create a regululatory science trail to punch out these approvals efficiently - in radiology.   (Paradigms, tools, standards, critical path, regulatory science, etc).  This makes sense for FDA, since it has tangible softwares (AI DOC, etc) in the review and approval pipeline. for radiology diagnostic reports.   (So far as I know, no parallel yet in the halls-of-FDA for pathology).

AI Researches the Cognita FDA AI Contract...500 words *or* 10pp

I asked Chat GPT to research and write up the FDA contract.  It did a great job.  After seeing its many pages of research, I asked it to file the information as a 500 word memo and as a 10 page full report.   As always, these AI reports should not be taken as ground truth but as examples of the current ability to understand a task, pursue it, and write it up.

500 word report on Cognita $1.2M Contract...HERE.

Ten page report on Cognita $1.2M Contract...HERE.

##

Schematic - 

Pathology, like radiology, needs to view a draft report as the digital output of digitized medicine - not a DICOM file delivered to the pathologist or radiologist.

##

Bonus - AMA essay and submission to FDA re regulatory path for LLM SAMD - here, here.

Labcorp Gets Bioreference: "Four Transcripts and a Funeral"

According to plans announced, Labcorp will acquire most remaining assets of Bioreference labs from OPKO. 

 See this new 12-page report developed entirely by AI from existing records, especially the past year of Investor Call transcripts.

Find it HERE: https://drive.google.com/file/d/1e9dQl6vaZLcGq1q2561iAWz4tSCjlJoZ/view?usp=sharing 

# # # 

The PDF above is an AI-generated document. It should not be used as ground truth. It provides an example of current AI abilities to understand instructions then write a report.

 ###

 On its first pass, Chat GPT initially just found and sifted the 4 investor call transcripts, here.  After reading that output, I asked for amplication into a "case study," as the PDF above.  It understood that "Case study" meant providing additional context, etc.   After that, I asked it to add a couple "sidebars," eg. on 4kScore.  Then, finally, "please make a PDF."

###

See the same approach - the "last 4 transcripts" - applied to Invitae here.

MolDx Withdraws Proposed NonCoverage of Prelude DCISionRT (0360U)

 On October 15, 2026, MolDx announced it was canceling its draft non-coverage LCD for Prelude's DCISionRT.  This follows recent announcements (1) first, the draft would be delayed and (2) and second, a CAC meeting 10/13 on the topic.

See message from CEO here.

I have updated my September 21 blog to keep the storyline in one place.

https://www.discoveriesinhealthpolicy.com/2026/09/when-does-moldx-change-its-mind-prelude.html

LabCorp Gets Bioreference, References 4K Score 81539

Bioreference acquisitioni by LabCorp features some  carve-outs for  4Kscore behavior.  Here's how it fared in recent Medicare Part B sales and in PAMA.

###

In 2025, Part B sales for 81539 were $12.6M for 16,500 units.

In 2024, Part B sales for 81339 were $11.7M for 15,300 units.

In 2023, Part B sales for 81339 were $10.4M for 13,700 units.

In current PAMA price data, 81539 has a 2026 price of $760, but its PAMA target price falls to $532, a ($228) or 30% drop.

Interestingly 11 TINS of commercial insurers reported 81539 pricing to PAMA, so I thought CMS might have also issued granular PAMA survey data, but there is none.   

Wholly unrelated data, CMS payments outbound to labs, showed 4 npi geting paid by CMS, but 99% of volume in 2024 paid from CMS to Bioreference (Opko Labs).

click to enlarge

.   

LabCorp Gets Bioreference: Two AI Viewpoints

Below find a Chat GPT and a CLAUDE review of the Labcorp-Bioreference acqiusition.  

Each had the same prompt (350-400, use internet).

This is AI  writing and should not be taken as ground truth.  It can be taken as an example of current AI research and writing skills.

###

Chat GPT

###

BioReference:

From OPKO’s Growth Platform

to Labcorp’s Consolidation Opportunity

OPKO acquired BioReference in 2015 through a stock transaction announced at $1.47 billion, but valued at approximately $950 million at closing after OPKO’s shares declined. The strategic ambition was clear: BioReference’s national sales and laboratory infrastructure would accelerate adoption of OPKO’s 4Kscore prostate cancer test and future diagnostics. 

Eleven years later, that distribution strategy is effectively being handed to Labcorp. OPKO Health, Inc. (OPK)

After a pandemic booom, the post-pandemic reversal was severe. In third-quarter 2022, BioReference’s COVID PCR volume fell to approximately 200,000 tests from 2.2 million a year earlier. 

OPKO’s diagnostics segment swung from $19.7 million in operating income to a $49.5 million loss. Management cut staffing and digital-health investment, revealing how difficult it was to resize the business after emergency testing demand evaporated. OPKO Health, Inc. (OPK)

Retrenchment became a sequence of sales. Labcorp bought clinical and women’s-health assets outside New York and New Jersey for $237.5 million in 2024. In 2025, Labcorp acquired oncology and related testing assets for $192.5 million upfront, with contingent consideration. OPKO presented the remaining regional laboratory -- and 4Kscore franchise -- as a more focused route to "sustainable profitability."  OPKO Health, Inc. (OPK)

Recent investor disclosures show why that destination remained elusive. Diagnostics lost $18.3 million in fourth-quarter 2025 and $13 million in first-quarter 2026. Second-quarter 2026’s reported $4.8 million operating profit included an $18.1 million earnout benefit from the previous Labcorp sale. Subtracting that benefit leaves approximately $13.3 million of operating loss. Shrinking the footprint had reduced losses without establishing durable profitability. opko.com

Yet October’s proposed transaction carries substantial value: $722 million, plus up to $150 million contingent on 4Kscore revenue. The upfront price equals approximately 2.9 times Labcorp’s projected $250 million first-year revenue from the acquired business. That suggests Labcorp sees considerable value in the customer relationships, specialty testing and opportunities within its larger network. Closing remains subject to approvals. opko.com

The parallel with Labcorp’s $239 million acquisition of Invitae assets through bankruptcy in 2024 is instructive, although BioReference’s transaction today is a negotiated divestiture. My reading is that both illustrate the value of combining distinctive diagnostics with national operating scale. OPKO gains capital and a sharper biopharmaceutical focus; Labcorp gains assets it believes can perform better within its infrastructure. The original promise of broader access for 4Kscore survives—but with a different owner delivering it. Labcorp